Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
Alimentary Pharmacology & Therapeutics · 2026-05 · 63 (10) · 1410-1420
DOI: 10.1111/apt.70574 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, published online on 2026-02-18. Written by Mariko Maxwell and 5 co-authors. Institution: Section of Digestive Diseases and Liver Center, Yale School of Medicine, New Haven, Connecticut, USA. Major MEDLINE topics: Fenofibrate, Liver Cirrhosis, Biliary, Hypolipidemic Agents. Cited 3 times so far (Crossref); 23 references.
Abstract (original language)
Background and Aims Nearly 40% of patients with primary biliary cholangitis (PBC) have an incomplete response to first‐line ursodeoxycholic acid (UDCA) therapy. Fenofibrate, a peroxisome proliferator‐activated receptor alpha (PPAR‐α) agonist, is an effective second‐line treatment for PBC. Compared to the recently FDA‐approved PPAR agonists, fenofibrate may provide a more cost‐effective and accessible alternative. However, longitudinal data on fenofibrate use in PBC are lacking. Here, we review our experience using fenofibrate in PBC and its long‐term effects on cholestatic biomarkers, prognostic scores, and fibrosis indices. Approach and Results This single‐centre retrospective cohort study examined PBC patients prescribed fenofibrate between 2012 and 2024 for persistent elevations in alkaline phosphatase (ALP) despite UDCA therapy. The study included 59 patients treated with fenofibrate for a mean duration of 44.8 months. The overall median time to ALP normalisation was 9.5 months. Of those who did not meet Paris II criteria prior to fenofibrate therapy, the median time to ALP normalisation was 11.2 months. GLOBE prognostic scores significantly improved with fenofibrate therapy, while UK‐PBC scores and fibrosis index scores (FIB‐4) remained stable. Fenofibrate was well‐tolerated by most patients, with only 5% of patients discontinuing therapy due to elevated liver enzymes. Conclusions In this long‐term cohort of PBC patients with insufficient response to UDCA, fenofibrate significantly improved cholestatic markers and prognostic scores over time. Given this, and its favourable safety profile, fenofibrate should be further considered as an accessible and affordable second‐line therapy in PBC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Section of Digestive Diseases and Liver Center, Yale School of Medicine, New Haven, Connecticut, USA.
- Yale School of Public Health, New Haven, Connecticut, USA.
ORCID profiles: Mariko Maxwell, James L Boyer, David N Assis
Cite
APA
Maxwell, M., Deng, Y., Chen, B., Silveira, M. G., Boyer, J. L., & Assis, D. N. (2026). Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study. Alimentary Pharmacology & Therapeutics, 63(10), 1410-1420. https://doi.org/10.1111/apt.70574
Vancouver
Maxwell M, Deng Y, Chen B, Silveira MG, Boyer JL, Assis DN. Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study. Alimentary Pharmacology & Therapeutics. 2026;63(10):1410-1420. doi:10.1111/apt.70574
BibTeX
@article{Maxwell2026,
author = {Maxwell, Mariko and Deng, Yanhong and Chen, Bonnie and Silveira, Marina G and Boyer, James L and Assis, David N},
title = {Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {10},
pages = {1410--1420},
doi = {10.1111/apt.70574}
}
EUVIMED